Ansa Biotechnologies is discovering more sustainable and accurate ways of synthesizing DNA. Currently, DNA is manufactured using a chemical method for various downstream applications from biological research, therapies, diagnostics to biomanufacturing. Ansa are changing this method by pioneering their enzyme-based approach that will be faster, cleaner and more accurate. Ansa’s enzymatic oligonucleotide synthesizer, published in Nature Biotechnology, involves template-independent polymerase-nucleotide conjugates. This approach could revolutionize the way DNA is made.

<p>Claim company profile to add description to this page.</p>


Ansa Biotechnologies

 Customer Experience Senior Associate

DNA Synthesis Associate

It's great connecting with the global #CGT community in New Orleans at #ASGCT2025! Swing by our booth (1252) to learn how Ansa is empowering gene therapy researchers to move faster, with more confidence.

Be sure to ask about the Ansa On-Time Guarantee and our new 50kb Early Access Program! 

And check out our recent paper describing how our enzymatic synthesis technology was able to resolve critical hurdles in viral vector-based gene therapy development—including synthesizing structurally complex ITRs and regulatory sequences—to create needed DNA on spec: https://bit.ly/3EmixUD

#celltherapy #genetherapy #ASGCT #DNAsynthesis #SyntheticDNA #complexDNA 


Synthesizing the Rules: How DNA Got Its Groove Back - SynBioBeta

 Oligonucleotide Synthesis Market: Advancements in DNA and ... 

Ansa Biotechnologies Sets New Standard in Long, Complex DNA - Business Wire

World’s Longest Oligo Produced Using de novo Synthesis - Genetic Engineering & Biotechnology News

Want to help us accelerate the rate of discovery and dramatically impact synthetic biology by building and support a growing and critical part of our operations? 

We’re #hiring a new DNA Synthesis Associate to help us develop and utilize automated systems. You would be one of the first members of our manufacturing team, and part of a dynamic, cross-functional, highly collaborative team operating at the interface between chemists, synthetic chemists, enzymologists, and automation experts in Emeryville, California. 

Apply today or pass along to someone who could fit the bill!

#sciencejobs #synbio #syntheticbiology #DNAsynthesis #automation #manufacturing 

Ansa Biotechnologies ties up $68M for DNA synthesis platform - Fierce Biotech

Rapid Rise of Synthetic Biology Fuels Enzymatic DNA Synthesis Boom Across Biopharma and Genomics - GlobeNewswire

Press Release Service: Ansa Biotechnologies Appoints Jason T. Gammack as CEO and Prepares for Launch of Rapid Enzymatic Synthesis Service for Complex DNA Sequences - CRISPR Medicine News

 Ansa Biotechnologies Sets New Standard in Long, Complex DNA 

A platform that allows protein secretion systems to achieve the same tuning capabilities seen in gene circuits? The Gao Lab has created just the thing, and it's made possible with enzymatic DNA synthesis by Ansa.

Connor Clayton Call of the Gao Lab at Stanford University will join Ansa co-founder and CSO Daniel Lin-Arlow to discuss the innovative Retained Endoplasmic Cleavable Secretion (#RELEASE) platform and its potential applications in re-wiring and regulating intercellular communication, with implications for cancer biology, immunology, and neuroscience.

They will also talk about the ins and outs of complex cloning strategies and the complexities involved with minimal sequence designs and repetitive motifs, which can be difficult without the modern DNA synthesis techniques that Ansa offers. 

🗓️ Register for the free Dec 10 webinar to learn more: https://lnkd.in/egZEGwWH

#DNAsynthesis #longDNA #Ansamers #biotech #synbio #SyntheticDNA #DNAInnovation #complexDNA  #customDNA #AnsamerAnswers

Ansa Bio Appoints Dr. Matthew McManus as Chair of the Board - Business Wire

Order Now

Assessment of enzymatically synthesized DNA for gene assembly - Frontiers

Ansa Biotechnologies selects new SVP of R&D - MM+M Online


              Ansa Biotechnologies Sets New Standard in Long, Complex DNA
            

More #SynBioBeta2025 research goodness: Take a peek at this poster by Greg Lohman of New England Biolabs about phage engineering using synthetic mycobacteriophages created with Ansa’s help.

With a high GC content (60-70%) and large size (50 kb+), the mycobacteriaphage genomes make PCR amplification and DNA synthesis difficult, and the in silico designed parts rated too complex for phosphoramidite synthesis by multiple vendors

But Ansa was able to synthesize all of the fragments submitted without issue, and the cloned & sequence verified parts permitted easy generation of high-quality DNA for Golden Gate Assembly and the insertion of anti-defense genes, laying the groundwork for therapeutics against hospital acquired mycobacterial infections.

Check out the poster for further details. 

#mycobacteriophages #phages #genomeengineering #vectordesign #DNAsynthesis #SynBioBeta #syntheticDNA #complexDNA 


👋 Greetings from #SanJose! We’re beyond excited for the start of #SynBioBeta2025! 

Stop by 𝗕𝗼𝗼𝘁𝗵 𝟯𝟭𝟮 to say hi, meet some customers, and grab some treats, including a free raffle ticket for a chance to win a fabulous prize! 

 • 𝗖𝗼𝗻𝗻𝗼𝗿 𝗖𝗹𝗮𝘆𝘁𝗼𝗻 𝗖𝗮𝗹𝗹 will be at the booth from 𝟭𝟬 - 𝟭𝟭 𝗮𝗺 to share how the 𝗚𝗮𝗼 𝗟𝗮𝗯 𝗮𝘁 𝗦𝘁𝗮𝗻𝗳𝗼𝗿𝗱 𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 has expanded the capabilities of traditional gene circuits into secretion protein circuits.
 • Greg Lohman from New England Biolabs will be at the booth from 𝟮-𝟯 𝗽𝗺 to talk about phage engineering using synthetic mycobacteriophages created with Ansa’s help. 

Hear from even more scientists who are rethinking what’s possible in vector design and genome engineering customers at our afternoon Breakout Panel Discussion.

📍 𝘗𝘶𝘴𝘩𝘪𝘯𝘨 𝘉𝘰𝘶𝘯𝘥𝘢𝘳𝘪𝘦𝘴: 𝘏𝘰𝘸 𝘙𝘦𝘭𝘪𝘢𝘣𝘭𝘦 𝘋𝘕𝘈 𝘚𝘺𝘯𝘵𝘩𝘦𝘴𝘪𝘴 𝘪𝘴 𝘈𝘤𝘤𝘦𝘭𝘦𝘳𝘢𝘵𝘪𝘯𝘨 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯 𝘪𝘯 𝘊𝘦𝘭𝘭 𝘢𝘯𝘥 𝘎𝘦𝘯𝘦 𝘛𝘩𝘦𝘳𝘢𝘱𝘺
📆 May 6 | 3:30–4:15 PM

 • Alex Cotton, PhD, Senior Scientist, Touchlight 
 • Aaron Larsen, Chief Scientific Officer, Terrain Biosciences 
 • Greg Lohman, Senior Principal Investigator, New England Biolabs
 • Sudarshan Pinglay, Research Fellow, University of Washington
 • Ania Wronski, Ph.D., Director of Technical Support, Ansa Biotechnologies, Inc.

#celltherapy #genetherapy #genomeengineering #vectordesign #DNAsynthesis #SynBioBeta #syntheticDNA #complexDNA 


 Jason T. Gammack on LinkedIn: I'm thrilled to be joining Ansa Biotechnologies, Inc. as CEO. Daniel… | 53 comments 

 Methods and systems for polymer synthesis by contacting synthesis surfaces with … 

Ansa Biotechnologies raises fund for DNA technology development - Pharmaceutical Technology

 Ansa Biotechnologies Raises $9.2 Million in Combined Seed and Pre-Seed Financing 

Ansa Biotechnologies Breaks Traditional Synthetic DNA Length Barriers and Redefines Future of Life Science Research - Business Wire

 Reversible terminators 

Thank you, Boston! We had a fantastic time connecting with attendees at #DDSS2025, and we can’t wait to meet West Coast researchers next week at The Scientist R&D Vendor Discovery Day!   

Learn how Ansa’s advanced synthesis platform can help you unlock complex sequences to drive deeper discoveries, and ask about the 𝗔𝗻𝘀𝗮 𝗢𝗻-𝗧𝗶𝗺𝗲 𝗚𝘂𝗮𝗿𝗮𝗻𝘁𝗲𝗲!

#SynBio #celltherapy #genetherapy #genomeengineering  #DNAsynthesis  #syntheticDNA #complexDNA The Scientist

Ansa Biotechnologies Announces Successful de novo Synthesis of World’s Longest Oligonucleotide at 1005 Bases - CRISPR Medicine News

𝗙𝗜𝗡𝗗 𝗨𝗦 𝗔𝗧 𝗧𝗜𝗗𝗘𝗦: Stop by Booth 7 in the Harbor Foyer to meet the Ansa team and learn how we’re helping therapeutic developers access the DNA they need.

🎉 And yes — we’re doing it again… We're giving away two clonal CONSTRUCTS (up to 7.5 kb). Enter to win one while you're here!  

Let’s talk about your DNA synthesis challenges — and how Ansa’s enzymatic platform is built to handle them.

#TIDESUSA #DNAsynthesis #SyntheticDNA #biotech #drugdevelopment #longDNA #complexDNA #genomics 


Ansa Biotechnologies Sets New Standard in Long, Complex DNA

The future of gene therapy depends on our ability to iterate faster, design smarter, and get exactly the DNA we want—no compromises.

At Ansa, we’re helping researchers push boundaries with complex, clonal synthetic DNA delivered on time, and on spec.

🧬 Learn how our platform is addressing long-standing pain points in viral vector and CGT development: https://lnkd.in/eT8aV8V6

📍#ASGCT2025 attendees can swing by booth 1252  to learn more — and enter to win a free construct up to 7.5kb!

#genetherapy #DNAsynthesis #celltherapy #biotech #CGT #ASGCT #SyntheticDNA #complexDNA 

And more great photos from our amazing cocktail event! What a view, and what a crew! 

Thanks for sharing , John Cumbers!

#SynBioBeta2025

Ansa Biotechnologies ties up $68M for DNA synthesis ...

This Company Is Using Enzymatic DNA Synthesis To Usher In The Next Generation Of Synthetic Biology Innovation - Forbes

Team Ansa is heading home from #SynBioBeta2025 energized, inspired, and grateful.

From launching our 50 kb Early Access Program to outstanding main stage talks and panel discussions, we were thrilled by the energy and excitement around the future of DNA synthesis.

Huge thanks to:

• Everyone who came to our booth and entered our raffle — and congratulations to Constructive Bio and Locbio on winning a free clonal construct (up to 7.5 kb)!
• Our incredible panelists and discussion partners who helped make “Pushing Boundaries” such a compelling breakout.
• All 90+ party guests who packed our cocktail celebration — your energy lit up the night!
• And of course, the amazing SynBioBeta team for pulling off another standout event.

💬 In case you missed our big news at the event, visit https://lnkd.in/eEvMRADK to learn about how to become a 50 kb early access customer.

#SyntheticBiology #DNAwithoutLimits #longDNA #biotech #synbio #SyntheticDNA #DNAInnovation #complexDNA #customDNA

 Ansa Biotechnologies Rolls Out Early Access Program for Long, Complex Synthetic DNA Orders 

With tremendous gratitude, we acknowledge all of those individuals who have dedicated their lives in service to our country. Thank you to everyone who is serving or has served. 🇺🇸

 Phosphoramidite Market Forecast 2025-2034: Comprehensive Insights on Market Size, Growth Factors, Trends 

The Ansa Biotechnologies team is ready for the holidays! From all of us, we wish you a season full of warmth, joy, and groundbreaking discoveries. Cheers to 2025! 🥂

#DNAsynthesis #longDNA #Ansamers #biotech #synbio #SyntheticDNA #DNAInnovation #complexDNA  #customDNA #HappyHolidays


Enzymatic DNA Synthesis: Going to Great Lengths - The Scientist

 Oligonucleotide Synthesis Market to Exceed 9.9 billion by ... 

 Ansa Biotechnologies Expands Leadership Team with Appointment of Jeremiah Hanes, Ph.D. as Senior Vice President of R&D 

 Enzymatic DNA Synthesis Market Key Manufacturers ... 

Startup Ansa Bio lands $68M to go long with enzymes approach to DNA synthesis - MedCity News

Ansa Biotechnologies Closes Oversubscribed $68 Million Series A Financing to Power the Next Era of DNA-Enabled Industries - Business Wire

IDT Lengthens DNA Offerings with Elegen Partnership - Genetic Engineering and Biotechnology News

 Ansa Biotechnologies Expands Successful Early Access Program for Complex DNA Synthesis 

Today, Ansa is launching our 50 kb early access DNA synthesis program, giving researchers access to longer, more complex constructs than ever before — in timelines that align with experimental reality.

Why does 50 kb matter?

  • It’s the difference between spending weeks on cloning vs. jumping straight to design
  • It allows for full viral vector constructs, operons, and complex regulatory regions in one go
  • It removes the need to “optimize” or compromise sequences just to make them buildable
  • And most importantly — it puts control back into the hands of scientists.

Our novel enzymatic synthesis platform builds long, difficult sequences — including high-GC, repetitive, or palindromic elements — with higher success rates and without chemical degradation. 

Those at #SynBioBeta2025 can stop by booth #312 to learn how you can build without limits and innovate without compromise.

Not attending? Get the details here:  https://lnkd.in/eNwtNt2Z

#SynBio #celltherapy #genetherapy #genomeengineering  #DNAsynthesis  #syntheticDNA #complexDNA #longDNA

 Ansa Biotechnologies to Showcase Early Access Customer Success at Upcoming Global Synthetic Biology Conference 

Ansa Biotechnologies Announces Successful de novo Synthesis of World’s Longest Oligonucleotide at 1005 Bases - Business Wire

Rewriting Cellular Communication: Advances in Synthetic Biology through Enzymatic DNA Synthesis for Protein Regulation - Fierce Biotech

 De novo stepwise template-independent synthesis of long polynucleotides 

 Ansa Biotechnologies partners with TeselaGen Biotechnology to enable commercial production of DNA products 

 Ansa Biotechnologies, Inc. on LinkedIn: Early Access 

Ansa Biotechnologies Expands Successful Early Access Program for Complex DNA Synthesis - Business Wire

We’re excited to welcome Ansa Biotechnologies, Inc. as a Bronze Level Sponsor for the International SynBYSS Conference! Join us at University of Hawai’i at Manoa from December 9-12, 2024. Don’t miss your chance to be part of this transformative experience-register today!

https://lnkd.in/eiQbZMZU


              Untangling the Complexities of Gene Synthesis for Longer, More Reliable DNA
            

 Ansa Biotechnologies Appoints Jason T. Gammack as CEO and Prepares for Launch of Rapid Enzymatic Synthesis ... 


              Hate Rejection? So Do We. Here’s Why Ansa Can Make the Complex DNA Other Vendors Can’t.
            

Discover 5 Top BioTech Startups advancing Enzyme Technology - StartUs Insights

 Cleavable linkers for the tethering of polymerases to nucleotides 

Ansa Biotech Raises $68M to Launch Customizable DNA Synthesis Service - BioSpace

 Enzymatic DNA Synthesis Market 2022: Explore Top Factors that Will Boost the Global Market by 2028 

Codex DNA Bets on Enzymatic Building Block Method for Gene Synthesis - GenomeWeb

 Methods of polynucleotide synthesis 

Ansa Biotechnologies Announces First Shipments of Complex Clonal DNA Sequences to Customers in Its Early Access Program - Technology Networks

SynBioBeta is here! 

Ansa's itinerary is action packed, with three speaking spots, a mixer, and our booth, where you can meet the team, learn all about the 𝗔𝗻𝘀𝗮 𝗢𝗻-𝗧𝗶𝗺𝗲 𝗚𝘂𝗮𝗿𝗮𝗻𝘁𝗲𝗲, and grab your free raffle ticket for a chance to win a fabulous prize!

Be sure to add the following to your ‘don’t miss’ list:

📍 𝘗𝘶𝘴𝘩𝘪𝘯𝘨 𝘉𝘰𝘶𝘯𝘥𝘢𝘳𝘪𝘦𝘴: 𝘏𝘰𝘸 𝘙𝘦𝘭𝘪𝘢𝘣𝘭𝘦 𝘋𝘕𝘈 𝘚𝘺𝘯𝘵𝘩𝘦𝘴𝘪𝘴 𝘪𝘴 𝘈𝘤𝘤𝘦𝘭𝘦𝘳𝘢𝘵𝘪𝘯𝘨 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯 𝘪𝘯 𝘊𝘦𝘭𝘭 𝘢𝘯𝘥 𝘎𝘦𝘯𝘦 𝘛𝘩𝘦𝘳𝘢𝘱𝘺
Customer Panel Discussion
📆 Tuesday, May 6 | 3:30–4:15 PM

📍 𝘙𝘦𝘷𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘪𝘻𝘪𝘯𝘨 𝘵𝘩𝘦 𝘊𝘶𝘴𝘵𝘰𝘮𝘦𝘳 𝘌𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦 𝘛𝘩𝘳𝘰𝘶𝘨𝘩 𝘚𝘦𝘢𝘮𝘭𝘦𝘴𝘴 𝘈𝘤𝘤𝘦𝘴𝘴 𝘵𝘰 𝘚𝘺𝘯𝘵𝘩𝘦𝘵𝘪𝘤 𝘋𝘕𝘈
Spotlight Talk - Main Stage
📆 Wednesday, May 7 | 10:45–10:55 AM

📍 𝘙𝘦𝘢𝘥𝘪𝘯𝘨 𝘢𝘯𝘥 𝘞𝘳𝘪𝘵𝘪𝘯𝘨: 𝘏𝘰𝘸 𝘍𝘢𝘳, 𝘏𝘰𝘸 𝘍𝘢𝘴𝘵, 𝘢𝘯𝘥 𝘞𝘩𝘦𝘯?
Panel Discussion - Main Stage 
📆 Wednesday, May 7 | 11:25–11:55 AM 

#DNAsynthesis #longDNA #biotech #synbio #SyntheticDNA #DNAInnovation #complexDNA #SynBioBeta2025 #customDNA

 Ansa Biotechnologies Pushes Limits of Complex DNA Synthesis with Launch of New Commercial Products 

Ansa Biotechnologies Names Jason T. Gammack as CEO Amid Advances in DNA Synthesis Technology - SynBioBeta

 Experts Bring a Faster and More Accurate Synthetic DNA Manufacturing Process 

"Trimming the Fat or Losing the Muscle? August 2024’s Biotech Layoff Frenzy Signals Strategic 'Adjustments' in the Name of Efficiency" - BSA bureau


                Ansa Biotechnologies Rolls Out Early Access Program for Long, Complex Synthetic DNA Orders
              

 Ansa Biotechnologies Names Jason T. Gammack as CEO Amid Advances in DNA Synthesis Technology 

 Ansa Biotechnologies Raises $68 Million In Series A Funding 

 DNA Supplier Ansa Biotechnologies Snares $68 Million 

 Ansa Biotechnologies Closes Oversubscribed $68 Million Series A Financing to Power the Next Era of DNA-Enabled Industries 

Ansa Biotechnologies Raises $9.2 Million in Combined Seed and Pre-Seed Financing - Business Wire

Missed #SynBioBeta2025? Well, you don’t have to miss out on the Ansa customer research that was presented! Learn how the Gao Lab at Stanford University has expanded the capabilities of traditional gene circuits into secretion protein circuits. 

They've developed a suite of protein engineering approaches to enable this level of programmability completely at the protein level, with potential uses in AAV vectors and mRNA for use in transient therapeutics.

💡Learn all about it in the attached poster

📺 You can also learn more in this webinar, now available on demand: https://bit.ly/4lS7lji

#AAV #mRNA #drugdevelopment #genomeengineering #vectordesign #DNAsynthesis #syntheticDNA #complexDNA #proteinengineering


 Ansa Biotechnologies Breaks Traditional Synthetic DNA Length Barriers and Redefines Future of Life Science Research 

It was great to attend and sponsor an event that celebrates and supports the next generation of synthetic biology innovators! We're looking forward to the next one! Thanks, J. Craig Venter Institute and Tae Seok Moon for making it happen!

#SynBYSS #synbio #syntheticbiology 

 Modified terminal deoxynucleotidyl transferase polymerases 

 Ansa Biotechnologies wants to usher in a new era of DNA manufacturing 

Ansa Biotechnologies wants to usher in a new era of DNA manufacturing - TechCrunch

Ansa Biotechnologies Pushes Limits of Complex DNA Synthesis with Launch of New Commercial Products - Business Wire

Lindsy Solanki - Cooley


              At Ansa, We're Enabling New Possibilities in Biological Engineering
            

Enzymatic DNA Synthesis Market Size & Share Report, 2030 - Grand View Research

Ansa Biotechnologies sets new standard in long complex DNA - SelectScience

Ansa Bio Appoints Lorna Neilson, Ph.D. as Chief Business Officer - Business Wire

‘Don’t want to fuss with this stuff’: Another DNA synthesis startup reels in funding - Endpoints News

𝗧𝗢𝗗𝗔𝗬! Mammalian synthetic biology is tricky, often requiring complex cloning strategies that can be difficult without modern DNA synthesis techniques.

The Gao Lab at Stanford have had to overcome these challenges in the development of the innovative Retained Endoplasmic Cleavable Secretion (𝗥𝗘𝗟𝗘𝗔𝗦𝗘) platform, which allows protein secretion systems to achieve the same tuning capabilities seen in gene circuits but focused solely on proteins.

It’s a great example of what enzymatic DNA synthesis can enable researchers to do, and we’re excited to highlight it in our next webinar.

🗓️ Tuesday, Dec. 10, 12pm ET

🔗 Sign up to watch live, or to get the recording: https://lnkd.in/egZEGwWH

#DNAsynthesis #longDNA #Ansamers #biotech #synbio #SyntheticDNA #DNAInnovation #complexDNA #customDNA #AnsamerAnswers

Ansa Biotechnologies Rolls Out Early Access Program for Long, Complex Synthetic DNA Orders - Genetic Engineering and Biotechnology News

 Compositions for enzymatic polynucleotide synthesis and methods of use 

⌛  It's the final countdown to #SynBioBeta2025, with just a week to go! We're especially excited about next Wednesday, May 7, when our CEO, Jason T. Gammack takes the stage for two must-see sessions:

 🧬 10:45–10:55 AM — 𝘙𝘦𝘷𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘪𝘻𝘪𝘯𝘨 𝘵𝘩𝘦 𝘊𝘶𝘴𝘵𝘰𝘮𝘦𝘳 𝘌𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦 𝘛𝘩𝘳𝘰𝘶𝘨𝘩 𝘚𝘦𝘢𝘮𝘭𝘦𝘴𝘴 𝘈𝘤𝘤𝘦𝘴𝘴 𝘵𝘰 𝘚𝘺𝘯𝘵𝘩𝘦𝘵𝘪𝘤 𝘋𝘕𝘈
A solo spotlight talk on how true reliability in DNA synthesis is accelerating innovation across synthetic biology.

🧬  11:25–11:55 AM — 𝘙𝘦𝘢𝘥𝘪𝘯𝘨 𝘢𝘯𝘥 𝘞𝘳𝘪𝘵𝘪𝘯𝘨: 𝘏𝘰𝘸 𝘍𝘢𝘳, 𝘏𝘰𝘸 𝘍𝘢𝘴𝘵, 𝘢𝘯𝘥 𝘞𝘩𝘦𝘯?
A lively panel discussion with industry leaders.

Join us later on the Marriott Hotel Sky View Suite to mix, mingle, and celebrate science together! Swing by 𝗕𝗼𝗼𝘁𝗵 𝟯𝟭𝟮 beforehand to snag a free raffle ticket for your chance to win a fabulous prize, and to learn more about the 𝗔𝗻𝘀𝗮 𝗢𝗻-𝗧𝗶𝗺𝗲 𝗚𝘂𝗮𝗿𝗮𝗻𝘁𝗲𝗲. 

 We can’t wait to see you there!

#SynBio #celltherapy #genetherapy #genomeengineering #vectordesign #DNAsynthesis #SynBioBeta #syntheticDNA #complexDNA

Ansa Biotechnologies

Business:

About: